Keyphrases
Cystic Fibrosis
86%
Asthma
37%
Pediatric
32%
European Respiratory Society
32%
Tobramycin
32%
Asthma Control
27%
Asthma children
21%
Adult Patients
20%
Inhaled Corticosteroids
18%
Sweat Test
18%
Barcelona
16%
Outpatient Visits
16%
Azithromycin
16%
Hepatic Function
16%
Intestinal Fat Absorption
16%
Electrical Properties
16%
Partial Recovery
16%
Exocrine Pancreatic Function
16%
Long-term Safety
16%
Function Properties
16%
Ivacaftor
16%
International Congresses
16%
Renal Function
16%
Inhalation
16%
Cotrimoxazole
16%
Pilocarpine
16%
Pediatric Pulmonologists
16%
Burkholderia Cepacia Complex
16%
Amiloride
16%
Pharmacy
16%
Target Attainment
16%
Medicinal Treatment
16%
Jejunoileal Atresia
16%
Weight Gain
10%
Fecal Elastase
10%
Treatment Adherence
10%
Inhalation Technique
10%
Ileal Atresia
10%
Jejunal Atresia
10%
HCl Solution
9%
Forced Expiratory Volume in 1 Second (FEV1)
8%
Atypical Asthma
8%
Maintenance Treatment
8%
Eradication Therapy
8%
Intravenous Antibiotics
8%
Intensive Care Medicine
8%
Inhaled Medications
8%
Oral Medication
8%
Cardiopulmonary Parameters
6%
Officers
5%
Medicine and Dentistry
Asthma
49%
Patient with Cystic Fibrosis
49%
Pediatrics
48%
Cystic Fibrosis
47%
Drug Therapy
38%
Tobramycin
35%
Asthma in Children
32%
Biological Marker
18%
Antibiotics
18%
Kidney Function
18%
Pseudomonas aeruginosa
17%
Burkholderia Cepacia Complex
16%
Azithromycin
16%
Pancreas Function
16%
Lipid Absorption
16%
Physical Activity
16%
Transplantation
16%
Ivacaftor
16%
Outpatient
16%
Liver Function
16%
Colistimethate
16%
Dry Powder Inhaler
16%
Congenital Pulmonary Airway Malformation
16%
Amiloride
16%
Eradication Therapy
16%
Trimethoprim/Sulfamethoxazole
16%
6 Diazo 5 Oxonorleucine
16%
Atresia
16%
Symptom
15%
Maintenance Therapy
12%
Elastase
10%
Sympathomimetic Drug
10%
QTc Interval
10%
Critical Appraisal
8%
Spirometry
6%
Treatment of Asthma
5%
Leukotriene Receptor Blocking Agent
5%
Cohort Effect
5%
Respiratory Tract Infection
5%
Neonatology
5%
Pancreatic Insufficiency
5%
Respiratory Physiology
5%
Immunology
5%
Drug Megadose
5%
Drug Dose Regimen
5%
Intensive Care
5%
Diagnosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Tobramycin
52%
Asthma
48%
Antibiotic Agent
25%
Pseudomonas aeruginosa
17%
Burkholderia Cepacia Complex
16%
Biological Marker
16%
Colistimethate
16%
Dry Powder Inhaler
16%
Azithromycin
16%
Pilocarpine
16%
Ivacaftor
16%
Adrenergic Receptor Stimulating Agent
16%
Ciclesonide
16%
Pharmacokinetics
16%
Amiloride
16%
Cotrimoxazole
16%
Symptom
14%
Elastase
10%
Leukotriene Receptor Blocking Agent
8%
Adverse Event
6%
Side Effect
6%
Fluticasone
5%
Pancreatic Insufficiency
5%
Budesonide
5%
